You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

63 Results
Cancer facts
Feb 2016
Cancer facts
Jan 2016
Cancer facts
Nov 2016
Guidelines and Advice
Status: In-Review
ID: 7-13
Oct 2017
Guidelines and Advice
Status: In-Review
ID: 19-6
Apr 2016
Guidelines and Advice
Status: Current
Version: 1
Mar 2018
Guidelines and Advice
Status: Archived
ID: 14-3
Jul 2005
Guidelines and Advice
Status: Archived
ID: 11-4
Sep 2011
Guidelines and Advice
Status: Current
ID: GL 17-12
Version: N/A
Sep 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to specific criteria.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iBRUtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For the treatment of patients with relapsed or refractory Waldenstrӧm Macroglobulinemia, as monotherapy, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iBRUtinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025

Pages